Latest News and Press Releases

Austin, United States, July 01, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The Multi-Cancer Early Detection Market was valued at USD 1.47 Billion in 2025 and is projected to reach USD 7.04...

Austin, United States, June 25, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, the Breast Cancer Liquid Biopsy Market Size was valued at USD 1.33 Billion in 2025 and is projected to reach USD...

CTA Approval from Germany's Federal Institute for Drugs and Medical Devices (BfArM), accompanied by a positive opinion from the Ethics Committee of the North Rhine Medical Association, clears Silexion...

Austin, United States, June 22, 2026 (GLOBE NEWSWIRE) -- The Laboratory Developed Tests Market was valued at USD 14.27 Billion in 2025 and is expected to reach USD 28.31 Billion by 2035, growing at...

Boehringer Ingelheim is committed to improving outcomes for people facing aggressive cancers where there are currently few treatment optionsDAREON®-Lung-1 and DAREON®-NEC-1 will evaluate obrixtamig as...

Grand Cayman, June 16, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for...

Austin, United States, June 03, 2026 (GLOBE NEWSWIRE) -- “The Liquid Biopsy Market size was valued at USD 6.39 Billion in 2025 and is projected to reach USD 36.78 Billion by 2035, growing at a CAGR...

Grand Cayman, May 26, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi)...

Israeli Ministry of Health approved the initiation of Silexion's Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer Clinical Trial Application subsequently submitted to Germany...

Grand Cayman, May 15, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi)...